Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunostimulatory nucleic acid molecules for activating dendritic cells

a technology of dendritic cells and nucleic acids, applied in the field of oligonucleotides, to achieve the effects of less toxic, less favorable th2 response, and higher th1 respons

Inactive Publication Date: 2007-03-22
UNIV OF IOWA RES FOUND
View PDF98 Cites 149 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

CpG oligonucleotides effectively activate dendritic cells, enhancing their survival, differentiation, and maturation, leading to improved immune responses and reduced toxicity, making them suitable for cancer, infectious disease, and allergy treatments.

Problems solved by technology

Unfortunately, toxic side effects has thus far prevented poly(IC) from becoming a useful therapeutic agent.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunostimulatory nucleic acid molecules for activating dendritic cells
  • Immunostimulatory nucleic acid molecules for activating dendritic cells
  • Immunostimulatory nucleic acid molecules for activating dendritic cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

Generation and Characterization of Dendritic Cells

Methods

[0122] Isolation of dendritic cells: Dendritic cells represent a small population of peripheral blood mononuclear cells (0.1 to 0.4%). They express substantial levels of CD4, but lack the T cell molecules CD3, CD8, and T cell receptor, and other lineage markers (CD19, CD14, CD16, CD56) (O'Doherty U, et al., “Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium”, J Exp Med, 1993; 178: 1067-1076). Using these characteristics, dendritic cells can be separated by high gradient immunomagnetic cell sorting using the VARIOMACS technique (Miltenyi Biotec Inc., Auburn, Calif.). Peripheral blood mononuclear cells were obtained from buffy coats of healthy blood donors (Elmer L. DeGowin Blood Center, University of Iowa) by Ficoll-Paque density gradient centrifugation (Histopaque-1077, Sigma Chemical Co., St. Louis, Mo.) as de...

example 2

CpG Substitutes for GMCSF for DC Survival

Methods

[0126] Oligodeoxynucleotides Unmodified (phosphodiester) and modified nuclease-resistant (phosphorothioate) oligodeoxyribonucleotide were purchased from Operon Technologies (Alameda, Calif.). The optimal motif recognized by human immune cells is different from the optimal mouse motif. Based on other studies in which we tested a large number of oligonucleotides for their ability to activate human B-cells and NK-cells, we selected particularly potent oligonucleotides as examples of a family of active CpG-containing oligonucleotides for the use in the present study. The CpG oligonucleotides used were: 2006 (24-mer), 5′-TCG TCG TTT TGT CGT TTT GTC GTT-3′ (SEQ ID NO: 84), completely phosphorothioate-modified, and 2080 (20-mer), 5′-TCG TCG TTC CCC CCC CCC CC-3′ (SEQ ID NO: 94), unmodified phosphodiester. The non-CpG control oligonucleotides used were: 2117 (24-mer), 5′-TQG TQG TTT TGT QGT TTT GTQ GTT-3′ (SEQ ID NO: 95), Q=5 methyl cytosin...

example 3

Increased Size and Granularity of DC Induced by CpG is Associated with Enhanced Expression of MHC II

Methods

[0130] Surface antigen staining At the indicated time points, cells were harvested and surface antigen staining was performed as previously described. Monoclonal antibodies to HLA-DR (Immu-357), CD80 (MAB104) and to CD83 (HB15A) were purchased from Immunotech, Marseille, France. All other antibodies were purchased from Pharmingen, San Diego, Calif.: mABs to CD1a (HI149), CD3 (UCHT1), CD14 (M5E2), CD19 (B43), CD40 (5C3), CD54 (HA58), CD86 (2331 (FUN-1)). FITC-labeled IgG1, κ (MOPC-21) and PE-labeled IgG2b, κ (27-35) were used to control for specific staining.

Results

[0131] Flow cytometric analysis suggested that differentiation of DC is enhanced by CpG and is associated with an increase of cell size (FSC) and granularity (SSC) (FIG. 1). The surface expression of MHC II is known to be positively correlated with differentiation of DC. DC isolated from peripheral blood were cu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The present invention relates generally to methods and products for activating dendritic cells. In particular, the invention relates to oligonucleotides which have a specific sequence including at least one unmethylated CpG dinucleotide which are useful for activating dendritic cells. The methods are useful for in vitro, ex-vivo, and in vivo methods such as cancer immunotherapeutics, treatment of infectious disease and treatment of allergic disease.

Description

RELATED APPLICATIONS [0001] This application is a divisional of co-pending U.S. Ser. No. 09 / 191,170, filed on Nov. 13, 1998, now allowed which is a continuation-in-part of U.S. Ser. No. 08 / 960,774, filed Oct. 30, 1997, now issued as U.S. Pat. No. 6,239,116B1 on May 29, 2001, which is a continuation-in-part of U.S. Ser. No. 08 / 738,652, filed Oct. 30, 1996 and which is now issued as U.S. Pat. No. 6,207,646B1 on Mar. 27, 2001, and which patent is a continuation-in-part of U.S. Ser. No. 08 / 386,063, filed Feb. 7, 1995 and which is now issued as U.S. Pat. No. 6,194,388B1 on Feb. 27, 2001, and which patent is a continuation-in-part of U.S. Ser. No. 08 / 276,358, filed Jul. 15, 1994 and which is abandoned, each of which are incorporated by reference.FIELD OF THE INVENTION [0002] The present invention relates generally to methods and products for activating dendritic cells. In particular, the invention relates to oligonucleotides which have a specific sequence including at least one unmethylat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/35A61K39/00C12N5/08C12N15/09A61K31/00A61K31/4706A61K39/39A61P37/04C07H21/00C12N5/0784C12Q1/68
CPCA61K31/00A61K31/4706A61K31/7048A61K31/711A61K31/7125A61K39/39C12Q1/68A61K2039/5158A61K2039/55561C07H21/00C12N5/0639C12N2501/056A61K2039/5156A61P37/04A61K39/464A61K39/4615A61K39/4622
Inventor KRIEG, ARTHUR M.HARTMANN
Owner UNIV OF IOWA RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com